Rangeley Capital LLC Takes $370,000 Position in Inhibikase Therapeutics, Inc. $IKT

Posted by Brenda Bartman on Jul 27th, 2026

Rangeley Capital LLC acquired a new stake in Inhibikase Therapeutics, Inc. (NASDAQ:IKT – Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor acquired 220,000 shares of the company’s stock, valued at approximately $370,000. Rangeley Capital LLC owned approximately 0.17% of Inhibikase Therapeutics as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. Sands Capital Alternatives LLC lifted its holdings in shares of Inhibikase Therapeutics by 18.9% during the 4th quarter. Sands Capital Alternatives LLC now owns 13,018,965 shares of the company’s stock valued at $26,689,000 after purchasing an additional 2,068,965 shares in the last quarter. ADAR1 Capital Management LLC boosted its holdings in Inhibikase Therapeutics by 53.7% during the fourth quarter. ADAR1 Capital Management LLC now owns 8,063,949 shares of the company’s stock worth $16,531,000 after purchasing an additional 2,816,346 shares during the last quarter. Siren L.L.C. bought a new position in shares of Inhibikase Therapeutics in the 4th quarter valued at about $11,992,000. Commodore Capital LP grew its stake in Inhibikase Therapeutics by 1.0% in the second quarter. Commodore Capital LP now owns 5,397,488 shares of the company’s stock valued at $10,525,000 after purchasing an additional 53,056 shares in the last quarter. Finally, Squadron Capital Management LLC bought a new position in shares of Inhibikase Therapeutics in the fourth quarter valued at $8,661,000. Institutional investors and hedge funds own 3.81% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on IKT shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Inhibikase Therapeutics in a research report on Friday, July 17th. Oppenheimer assumed coverage on shares of Inhibikase Therapeutics in a research report on Wednesday, June 10th. They issued an “outperform” rating and a $5.00 price objective on the stock. Wall Street Zen upgraded shares of Inhibikase Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Sunday. Finally, LADENBURG THALM/SH SH raised shares of Inhibikase Therapeutics to a “strong-buy” rating in a report on Monday, July 13th. Four analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $5.40.

Check Out Our Latest Research Report on IKT

Inhibikase Therapeutics Stock Performance

Shares of NASDAQ:IKT opened at $2.33 on Monday. The firm has a 50 day moving average of $1.86 and a 200-day moving average of $1.81. Inhibikase Therapeutics, Inc. has a 12 month low of $1.33 and a 12 month high of $2.53. The stock has a market capitalization of $307.63 million, a PE ratio of -5.42 and a beta of 0.94.

Inhibikase Therapeutics (NASDAQ:IKT – Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported ($0.10) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.10). On average, research analysts predict that Inhibikase Therapeutics, Inc. will post -0.42 EPS for the current fiscal year.

About Inhibikase Therapeutics

(Free Report)

Inhibikase Therapeutics, Inc, a clinical stage pharmaceutical company, develops therapeutics for Parkinson’s Disease (PD) and related disorders that arise inside and outside of the brain. The company’s product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.